GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (LTS:0A3M) » Definitions » EV-to-FCF

BioNTech SE (LTS:0A3M) EV-to-FCF : 10.59 (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioNTech SE's Enterprise Value is $10,854 Mil. BioNTech SE's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $1,025 Mil. Therefore, BioNTech SE's EV-to-FCF for today is 10.59.

The historical rank and industry rank for BioNTech SE's EV-to-FCF or its related term are showing as below:

LTS:0A3M' s EV-to-FCF Range Over the Past 10 Years
Min: -264.96   Med: 1.04   Max: 74.92
Current: 10.08

During the past 8 years, the highest EV-to-FCF of BioNTech SE was 74.92. The lowest was -264.96. And the median was 1.04.

LTS:0A3M's EV-to-FCF is ranked worse than
52.2% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs LTS:0A3M: 10.08

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), BioNTech SE's stock price is $121.50. BioNTech SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.081. Therefore, BioNTech SE's PE Ratio (TTM) for today is At Loss.


BioNTech SE EV-to-FCF Historical Data

The historical data trend for BioNTech SE's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE EV-to-FCF Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -23.74 -152.45 72.80 1.56 1.43

BioNTech SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 1.43 0.96 0.30 9.95

Competitive Comparison of BioNTech SE's EV-to-FCF

For the Biotechnology subindustry, BioNTech SE's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNTech SE's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioNTech SE's EV-to-FCF falls into.



BioNTech SE EV-to-FCF Calculation

BioNTech SE's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10853.600/1025.048
=10.59

BioNTech SE's current Enterprise Value is $10,854 Mil.
BioNTech SE's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,025 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioNTech SE  (LTS:0A3M) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BioNTech SE's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=121.50/-2.081
=At Loss

BioNTech SE's share price for today is $121.50.
BioNTech SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.081.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioNTech SE EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioNTech SE's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNTech SE Business Description

Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

BioNTech SE Headlines

No Headlines